Related coverage linked through entity extraction aliases.
Mar 14, 2026
A secondary analysis of the OPTIMUM trial found that higher doses of bupropion and prior fall history significantly increase fall risk in older adults with treatment-resistant depression receiving antidepressant augmentation.
Mar 09, 2026
Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.
Mar 09, 2026
COMPASS Pathways announced positive Phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant improvements across two pivotal trials with durability signals through 26 weeks and a generally well-tolerated safety profile.
